The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
“Wheelbarrowing is a big word, but I have looked at the website info and they are clear as mud. Can anyone explain in layman's terms”
A wheelbarrow is a small hand-propelled vehicle, usually with just one wheel, designed to be pushed and guided by a single person using two handles at the rear, or by a sail to push the ancient wheelbarrow by wind. The term "wheelbarrow" is made of two words: "wheel" and "barrow." "Barrow" is a derivation of the Old English "barew" which was a device used for carrying loads.
A common wheelbarrow.
The wheelbarrow is designed to distribute the weight of its load between the wheel and the operator, so enabling the convenient carriage of heavier and bulkier loads than would be possible were the weight carried entirely by the operator. As such it is a second-class lever. Traditional Chinese wheelbarrows, however, had a central wheel supporting the whole load. Use of wheelbarrows is common in the construction industry and in gardening. Typical capacity is approximately 100 litres (3.53 cubic feet) of material.
A two-wheel type is more stable on level ground, while the almost universal one-wheel type has better maneuverability in small spaces, on planks, in water, or when tilted ground would throw the load off balance. The use of one wheel also permits greater control of the deposition of the load upon emptying :-)
Below text taken directly from 29th Sept RNS.....Can certain people on the BB not read or are they simply just plain stupid.
Dr Alastair Smith, Chief Executive of Avacta Group plc, commented:
"The strong momentum in the Group seen during the first half of 2022 has continued post-period end. Most notably the Phase I clinical trial evaluating the safety and tolerability of AVA6000 is making excellent progress and is NOW RECRUITING patients into the fourth dose escalation cohort, at a dose of 200 mg/m2, equivalent to more than double the normal dose of doxorubicin.
What do people not understand about the phrase "NOW RECRUITING" ffs the data will be released when they are ready, and BTW they are still on track for Q4
My wife’s best pal knows someone very well who is currently on a trial at The Beatson in Glasgow. Initial conversations with her pal strongly suggest it’s undoubtedly the AVA6000 trial but I definitely won’t be probing for more detailed info. The moral of this story is many people will start to know something about this trial as it progresses. The UK is a very small country so news will spread relatively quickly. I have known this info for a while now but thought it was utterly pointless to post until today. Like I previously said I won’t be probing for more info unless my wife’s pal mentions something. So in conclusion I personally definitely believe Mr R’s post today and anyone else for that matter who has a similar story over the coming days / weeks.
Touk, from memory AVCT will not provide a blow by blow account on how the trial is progressing for ethical reasons. However, I stand to be corrected on that.
Anyway, as far as I'm concerned no news is definitely good news at this point of the trial.
Heading in the right direction again, we have all seen this before but I think this time it's different. All being well we will eventually get a very positive update from TRX. Break even or showing a profit would be really nice to see :-)
Tomorrow morning, the next morning or the next etc, etc, etc. What will make the difference is when initial results are published. Reading the investor key information Bella so kindly posted IMO makes success as plain as the nose on my face. Combined with additional bullish statements from AVCT and employees it's now becoming obvious something big is going to be announced before EOY. If AVCT failed to deliver AS and his company would look so stupid, I really don't think he would willingly put himself in that position, the man is clearly not an idiot.
rxdav 20:23, Jeez, cringe worthy doesn’t have a look in. Mr R must have even thought WTF is all that about :-) Anyway, no doubt we can all agree the board has been entertaining tonight :-)…..looking fwd to Saturday nights entertainment :-)
Mr R keep up the teflon shoulders because at the end of the day everyone on this BB has an agenda…..hopefully to make loads a money :-)
@Toukankahmoon “Be sh*77yy if they RNS tomorrow before we’ve had our cash returned and therefore can’t buy more shares before the”boom”.
Touk, surely you are not over exposed !!! Someone like you with supposedly 40 years investing experience should no better.
Below extract taken directly from 29th Sept Results RNS.....note the comment "now recruiting patients into fourth dose escalation cohort", could easily be delays until we hopefully hear good news. Certain posters on here putting a timeframe on results etc, etc is nothing short of ridiculous IMO. Don't get me wrong, I will be delighted if positive news arrives tomorrow or the next day etc but until the RNS arrives I certainly won't be holding my breath.
Dr Alastair Smith, Chief Executive of Avacta Group plc, commented:
"The strong momentum in the Group seen during the first half of 2022 has continued post-period end. Most notably the Phase I clinical trial evaluating the safety and tolerability of AVA6000 is making excellent progress and is now recruiting patients into the fourth dose escalation cohort, at a dose of 200 mg/m2, equivalent to more than double the normal dose of doxorubicin".
“Joe, the trial is about safety, so theoretically (because I have already stated I don' think this is happening, but what do I know), if for the sake of argument, the AVCT bit was making no difference then you would up the dose to see if that made the tech work as long as the patient was not being harmed. The 2 are (or could be) exclusive.
Isn't that the whole point of this part of the trial?”
Wyn, the statement you made above suggests the patients are simply being treated as cannon fodder, I very much doubt that would be allowed !!!
“It could be, that its making no difference to the patient and they keep upping the dosage in the hope it will "work". “
Wyn, I’m no expert, however, I can’t imagine the safety reviewing committee allowing the trial to continue if the patients were not obtaining any benefits over and above normal DOX dosing.
"investor presentations and business updates are hooks for finance"
Yeah, they sure are, you should have added "line and sinker" after hooks.
Not that long ago AVCT presentations etc were stating astronomical LFT sales, remember that !!!